Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc.verified

ATRA

Price:

$12.708

Market Cap:

$73.19M

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of...[Read more]

Industry

Biotechnology

IPO Date

2014-10-16

Stock Exchange

NASDAQ

Ticker

ATRA

The Enterprise Value as of December 2024 (TTM) for Atara Biotherapeutics, Inc. (ATRA) is 76.64M

According to Atara Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 76.64M. This represents a change of -20.02% compared to the average of 95.82M of the last 4 quarters.

Atara Biotherapeutics, Inc. (ATRA) Historical Enterprise Value (quarterly & annually)

How has ATRA Enterprise Value performed in the past?

The mean historical Enterprise Value of Atara Biotherapeutics, Inc. over the last ten years is 689.21M. The current 76.64M Enterprise Value has changed 1.01% with respect to the historical average. Over the past ten years (40 quarters), ATRA's Enterprise Value was at its highest in in the March 2019 quarter at 1.80B. The Enterprise Value was at its lowest in in the September 2024 quarter at 64.15M.

Quarterly (TTM)
Annual

Average

689.21M

Median

556.85M

Minimum

86.34M

Maximum

1.46B

Atara Biotherapeutics, Inc. (ATRA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Atara Biotherapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 484.78%

Maximum Annual Enterprise Value = 1.46B

Minimum Annual Increase = -369.73%

Minimum Annual Enterprise Value = 86.34M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202386.34M-72.44%
2022313.29M-77.55%
20211.40B10.35%
20201.26B61.14%
2019784.86M-46.32%
20181.46B216.60%
2017461.80M28.27%
2016360.03M-44.77%
2015651.90M484.78%
2014111.48M-369.73%

Atara Biotherapeutics, Inc. (ATRA) Average Enterprise Value

How has ATRA Enterprise Value performed in the past?

The current Enterprise Value of Atara Biotherapeutics, Inc. (ATRA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

598.44M

5-year avg

768.98M

10-year avg

689.21M

Atara Biotherapeutics, Inc. (ATRA) Enterprise Value vs. Peers

How is ATRA’s Enterprise Value compared to its peers?

Atara Biotherapeutics, Inc.’s Enterprise Value is less than Fate Therapeutics, Inc. (250.70M), less than Sana Biotechnology, Inc. (357.58M), less than Caribou Biosciences, Inc. (146.80M), less than Arcus Biosciences, Inc. (1.30B), less than Heron Therapeutics, Inc. (395.10M), less than Allogene Therapeutics, Inc. (460.58M), less than BioXcel Therapeutics, Inc. (81.20M), less than Karyopharm Therapeutics Inc. (199.95M), less than X4 Pharmaceuticals, Inc. (77.01M), greater than HOOKIPA Pharma Inc. (-38483912.00), less than Mereo BioPharma Group plc (510.92M), greater than Galera Therapeutics, Inc. (-6763403.00), less than Acumen Pharmaceuticals, Inc. (104.95M), less than VectivBio Holding AG (848.58M), less than Icosavax, Inc. (713.87M), less than Apellis Pharmaceuticals, Inc. (4.22B), less than iTeos Therapeutics, Inc. (155.42M), less than TScan Therapeutics, Inc. (115.21M),

Build a custom stock screener for Atara Biotherapeutics, Inc. (ATRA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atara Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Atara Biotherapeutics, Inc. (ATRA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Atara Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Atara Biotherapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Atara Biotherapeutics, Inc. (ATRA)?

What is the 3-year average Enterprise Value for Atara Biotherapeutics, Inc. (ATRA)?

What is the 5-year average Enterprise Value for Atara Biotherapeutics, Inc. (ATRA)?

How does the current Enterprise Value for Atara Biotherapeutics, Inc. (ATRA) compare to its historical average?